Core Viewpoint - A class action lawsuit has been filed against LifeMD, Inc. for allegedly misleading investors about its business prospects during the period from May 7, 2025, to August 5, 2025 [1][2]. Group 1: Allegations and Misconduct - The lawsuit claims that LifeMD's management materially overstated the company's competitive position and recklessly raised its 2025 guidance without properly accounting for rising customer acquisition costs in its RexMD segment and related to obesity treatment drugs [2]. - The defendants' statements regarding LifeMD's business operations and prospects were allegedly materially false and misleading, lacking a reasonable basis throughout the relevant period [2]. Group 2: Financial Impact - Following the announcement of its second quarter 2025 results on August 5, 2025, which indicated temporary challenges in the RexMD business, LifeMD revised its full-year 2025 revenue and adjusted EBITDA guidance, leading to a significant stock price drop of $5.31 per share, or 44.8%, closing at $6.53 on August 6, 2025 [3]. Group 3: Legal Proceedings - Shareholders interested in participating as lead plaintiffs in the class action must file their papers with the court by October 27, 2025 [4]. - The lead plaintiff will represent other class members in directing the litigation, although participation is not required to be eligible for recovery [4]. Group 4: Company Background - Robbins LLP, the law firm handling the case, has been dedicated to helping shareholders recover losses and improve corporate governance since 2002 [5].